Therapeutically active compounds and their methods of use

Abstract

Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.

1 - 19 . (canceled) 
     
     
         20 . A compound which is 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt or hydrate thereof. 
       
     
     
         21 . A pharmaceutical composition comprising a compound of  claim 20 , and a pharmaceutically acceptable carrier. 
     
     
         22 . A method of treating a cancer characterized by the presence of an IDH2 mutation, wherein the IDH2 mutation results in a new ability of the enzyme to catalyze the NADPH dependent reduction of a ketoglutarate to R(−) 2 hydroxyglutarate in a patient, comprising the step of administering to the patient in need thereof a compound of  claim 20 . 
     
     
         23 . The method of  claim 22 , wherein the IDH2 mutation is an IDH2 R140Q or R172K mutation. 
     
     
         24 . The method of  claim 22 , wherein the IDH2 mutation is an IDH2 R140Q mutation. 
     
     
         25 . The method of  claim 22 , wherein the cancer is selected from the group consisting of glioblastoma, myelodysplastic syndrome, myeloproliferative neoplasm, acute myelogenous leukemia, sarcoma, melanoma, non small cell lung cancer, chondrosarcoma, cholangiocarcinomas and angioimmunoblastic non-Hodgkin's lymphoma. 
     
     
         26 . The method of  claim 22 , wherein the cancer is acute myelogenous leukemia. 
     
     
         27 . The method of  claim 22 , further comprising administering to the patient in need thereof a second therapeutic agent useful in the treatment of cancer.